Palatin Technologies Inc. (PTN)

[mikedeatworld]

I agree. A partnership brings validity to the company, the drug itself and the possibility of an FDA approval.

A buyout, would be the ideal situation. I think the odds of that happening are high. The CEO has said, that basically someone will buy Sprouts drug once approved (that happened) and that someone will buy Bremelanotide when it is approved (is this happening right now behind closed doors?)


Quote:
I think the main question is really the regulatory uncertainty, and that has been changing. And so I think as the regulatory uncertainty hopefully gets clarified coming out of the June 4 meeting, and then I guess, a little later in the year, should the panel recommend approval, hopefully that drug getting approved, I think that really helps to remove one of the remaining obstacles that we see to finalizing a substantial transaction for bremelanotide.
There are only two of us in the marketplace, I mean there is flibanserin and there's bremelanotide, so there are lot of companies that sell into the OB/GYN space, so if one gets one, somebody is going to need another one. So I think we'd be well-positioned.